custom search
REVERSED
1600 Biotechnology and Organic Chemistry
1654 Ex Parte Carpenter et al 10271832 - (D) GRIMES 112(1)/102 Endo Pharmaceuticals Inc. c/o Marsh Fischmann & Breyfogle LLP GUPTA, ANISH
1700 Chemical & Materials Engineering
1723 Ex Parte Luo et al 10996218 - (D) PER CURIAM 103 GENERAL ELECTRIC COMPANY MENDEZ, ZULMARIAM
1726 Ex Parte Fukumoto et al 11520571 - (D) HOUSEL 103 MCDERMOTT WILL & EMERY LLP RHEE, JANE J
1782 Ex Parte Wang et al 10241278 - (D) BEST 102/103 VIDAS, ARRETT & STEINKRAUS, P.A. PATTERSON, MARC A
3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3623 Ex Parte Doerfler et al 11213168 - (D) KIM 103 37 C.F.R. § 41.50(b) 103 SAP/BSTZ BLAKELY SOKOLOFF TAYLOR & ZAFMAN JACKSON, ERNEST ADEYEMI
3635 Ex Parte Near et al 11731066 - (D) SAINDON 103 JOHNS MANVILLE KATCHEVES, BASIL S
3700 Mechanical Engineering, Manufacturing, and Products & Design
3731 Ex Parte Clague et al 10694037 - (D) KAUFFMAN 103 Medtronic CardioVascular NGUYEN, TUAN VAN
3734 Ex Parte Valencia 11526326 - (D) SCHEINER 103 VIDAS, ARRETT & STEINKRAUS, P.A. BACHMAN, LINDSEY MICHELE
3739 Ex Parte Scott et al 11238698 - (D) MILLS 112(2)/102/103 PATENT DEPT - INTUITIVE SURGICAL OPERATIONS GOOD, SAMANTHA M
3763 Ex Parte Kusleika 10825309 - (D) FRANKLIN 103 KENYON & KENYON LLP VU, QUYNH-NHU HOANG
3773 Ex Parte Vogel et al 11363426 - (D) SAINDON 102/103 Klaus J. Bach MASHACK, MARK F
“[W]hen the PTO shows sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not.” In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990) (citing In re King, 801 F.2d 1324, 1327 (Fed. Cir. 1986) and In re Ludtke, 441 F.2d 660, 664 (CCPA 1971)). In this case, however, the Examiner has not shown a sound basis to shift the burden to Appellants.
Spada, In re, 911 F.2d 705, 15 USPQ2d 1655 (Fed. Cir. 1990) . . . . . . . . . . . . . . . . . 2112.01
King, In re, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir.1986) . . . . . . .1206, 2112.02, 2131.01
Ludtke, In re, 441 F.2d 660, 169 USPQ 563 (CCPA 1971) . . . . . . . . . . . . . . . . . . . .2112.01
3778 Ex Parte Calvert 11277571 - (D) ADAMS 102/103 Shumaker, Loop & Kendrick, LLP HAND, MELANIE JO
AFFIRMED-IN-PART
1700 Chemical & Materials Engineering
1711 Ex Parte Czyzewski et al 11044396 - (D) OWENS 103 103 BSH HOME APPLIANCES CORPORATION RIGGLEMAN, JASON PAUL
1727 Ex Parte Vyas et al 11201767 - (D) PAK 103 103/obviousness-type double patenting MILLER IP GROUP, PLC GENERAL MOTORS CORPORATION ENIN-OKUT, EDU E
2400 Networking, Multiplexing, Cable, and Security
2448 Ex Parte Schoenfeld 10693423 - (D) GONSALVES 103 103 Fogarty, L.L.C. VU, VIET DUY
AFFIRMED
1600 Biotechnology and Organic Chemistry
1631 Ex Parte Ishikawa et al 10925905 - (D) GREEN 103 THE INVENTION SCIENCE FUND CLARENCE T. TEGREENE SKIBINSKY, ANNA
1700 Chemical & Materials Engineering
1724 Ex Parte Prohaska et al 11169936 - (D) OWENS 103 ST. ONGE STEWARD JOHNSTON & REENS, LLC OLSEN, KAJ K
1774 Ex Parte Martin et al 10006875 - (D) ROBERTSON 102/103 CHEVRON U.S.A. INC. DUONG, THANH P
2100 Computer Architecture and Software
2179 Ex Parte Poerner et al 10666227 - (D) McNAMARA 103 Siemens Corporation LO, WEILUN
2400 Networking, Multiplexing, Cable, and Security
2427 Ex Parte Young 10621227 - (D) McNAMARA 103 SCHWEGMAN, LUNDBERG & WOESSNER, P.A. INGVOLDSTAD, BENNETT
2457 Ex Parte Orhomuru 09862789 - (D) DIXON 102/103 WILLIAMSON INTELLECTUAL PROPERTY LAW, LLC JACOBS, LASHONDA T
We first note that Appellant employs the Markush group format in claim 5 by reciting “selecting an operation from the group consisting of accessing data . . . , posting data . . . , updating data . . . , deleting data . . . , and combinations thereof.” See MPEP § 2173.05(h)(I). Accordingly, Xu discloses the “selecting” step if Xu discloses selecting one of the recited operations in the group. See Fresenius USA, Inc. v. Baxter Int’l, Inc., 582 F.3d 1288, 1298 (2009) (“[T]he entire element is disclosed by the prior art if one alternative in the Markush group is in the prior art.”) (citing Schering Corp. v. Geneva Pharms., Inc., 339 F.3d 1373, 1380 (Fed. Cir. 2003)).
Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 67 USPQ2d 1664 (Fed. Cir. 2003). . . . . .2112
3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3677 Ex Parte HASHIGUCHI et al 09166233 - (D) MORRISON 103 BACON & THOMAS, PLLC MILLER, WILLIAM L
3700 Mechanical Engineering, Manufacturing, and Products & Design
3731 Ex Parte Wilson et al 11606620 - (D) FRANKLIN 103 Lawrence Livermore National Security, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY EASTWOOD, DAVID C
3737 Ex Parte Tarakci et al 11189437 - (D) ADAMS 112(2)/103 CARR & FERRELL LLP HUNTLEY, DANIEL CARROLL
3778 Ex Parte Song et al 10902998 - (D) FRANKLIN 103 THE PROCTER & GAMBLE COMPANY HAND, MELANIE JO
REHEARING
DENIED
1600 Biotechnology and Organic Chemistry
1613 Ex Parte Davenport et al 10121325 - (D) WALSH 103 THE PROCTER & GAMBLE COMPANY FUBARA, BLESSING M
